Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal women who meet at least one of the following bone mineral density (BMD) and fracture criteria:~* BMD T-score at the total hip or femoral neck of ≤ -2.50 and EITHER:~  * at least 1 moderate (semiquantitative grade \[SQ\]2) or severe (SQ3) vertebral fracture OR~ * at least 2 mild (SQ1) vertebral fractures OR~* BMD T-score at the total hip or femoral neck of ≤ -2.00 and EITHER:~  * at least 2 moderate (SQ2) or severe (SQ3) vertebral fractures OR~ * a fracture of the proximal femur that occurred within 3 to 24 months prior to randomization.~Exclusion Criteria:~* History of metabolic or bone disease (except osteoporosis)~* Use of agents affecting bone metabolism~* Vitamin D insufficiency~* History of solid organ or bone marrow transplants~* Hyper- or hypocalcemia~* Hyper- or hypothyroidism~* Hyper- or hypoparathyroidism~* Possible signs of intolerance to alendronate

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Alendronate/Alendronate (Type: ACTIVE_COMPARATOR): Participants received 70 mg alendronate once a week and placebo to romosozumab subcutaneously once a month for the first 12 months. After completion of the 12-month double-blind treatment period participants continued to receive 70 mg alendronate once a week until the end of the study.
- Romosozumab/Alendronate (Type: EXPERIMENTAL): Participants received 210 mg romosozumab subcutaneously once a month and placebo to alendronate orally once a week for the first 12 months. After completion of the 12-month double-blind treatment period participants received 70 mg alendronate once a week until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).